Widespread renal polycystosis induced by crizotinib

Tumori

Volumn 101, Issue 4, 2015, Pages e128-e131

  Di Girolamo, Marco ^a   Paris, Ida ^a   Carbonetti, Francesco ^a   Onesti, Elisa Concetta ^a   Socciarelli, Fabio ^a   Marchetti, Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Adverse reactions; Drug related side effects; Kidney diseases; Lung neoplasms; Therapeutics

Indexed keywords

CERITINIB; CISPLATIN; CRIZOTINIB; PEMETREXED; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

AGED; ALK GENE; ARTICLE; BOSNIAK CLASSIFICATION; CANCER CLASSIFICATION; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE TRANSLOCATION; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; KIDNEY POLYCYSTIC DISEASE; LUNG ADENOCARCINOMA; LYMPHADENOPATHY; MALE; ONCOGENE; ADENOCARCINOMA; ANTAGONISTS AND INHIBITORS; BONE TUMOR; BRAIN NEOPLASMS; CHEMICALLY INDUCED; CYST; DIAGNOSTIC USE; ELECTRON MICROSCOPY; GENETICS; KIDNEY DISEASE; LIVER TUMOR; LUNG NEOPLASMS; MOLECULARLY TARGETED THERAPY; NEEDLE BIOPSY; PATHOLOGY; PROCEDURES; RADIOGRAPHY; SECONDARY;

ADENOCARCINOMA; AGED; ANTINEOPLASTIC AGENTS; BIOPSY, NEEDLE; BONE NEOPLASMS; BRAIN NEOPLASMS; CONTRAST MEDIA; CYSTS; HUMANS; KIDNEY DISEASES; LIVER NEOPLASMS; LUNG NEOPLASMS; MALE; MICROSCOPY, ELECTRON; MOLECULAR TARGETED THERAPY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; TOMOGRAPHY, X-RAY COMPUTED; TRANSLOCATION, GENETIC;

EID: 84942872538     PISSN: 03008916     EISSN: 20382529     Source Type: Journal    
DOI: 10.5301/tj.5000338     Document Type: Article

References (13)

1. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385-94.
2. Brosnan EM, Weickhardt AJ, Lu X, et al. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer. 2014;120:664-74.
3. Klempner SJ, Aubin G, Dash A, Ou SH. Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment. Oncologist. 2014;19:1008-10.
4. Heigener DF, Reck M. Crizotinib: recent results. Cancer Res. 2014;201:197-205.
5. XALORI US Physician Prescribing Information. Available at: http://labeling.pfizer.com/showlabeling.aspx?id=676. Accessed November 2014. (25-11-2014).
6. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008;26:3543-51.
7. Jhaveri K, Gupta P, Elmi A, et al. Cystic renal cell carcinomas: do they grow, metastasize, or recur? AJR Am J Roentgenol. 2013;201:W292-6.
8. Huber J, Winkler A, Jakobi H, et al. Preoperative decision making for renal cell carcinoma: cystic morphology in cross-sectional imaging might predict lower malignant potential. Urol Oncol. 2014;32:37.
9. Shaw AT, Kim DW, Mehra R, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370:1189-97.
10. Heller MT, Haarer KA, Thomas E, Thaete FL. Neoplastic and proliferative disorders of the perinephric space. Clin Radiol. 2012;67:e31-41.
11. Curry NS, Cochran ST, Bissada NK. Cystic renal masses: accurate Bosniak classification requires adequate renal CT. AJR Am J Roentgenol. 2000;175:339-42.
12. Israel GM, Bosniak MA. How I do it: evaluating renal masses. Radiology. 2005;236:441-50.
13. Bata P, Tarnoki AD, Tarnoki DL, et al. Bosniak category III cysts are more likely to be malignant than we expected in the era of multidetector computed tomography technology. J Res Med Sci. 2014;19:634-8.